Arrowhead Research | ARWR - Ebitda

Stock Price
76.67
Daily Change
-3.02 -3.79%
Monthly
12.78%
Yearly
388.03%
Q2 Forecast
75.13

Arrowhead Research reported $57.17M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 57.17M 7.03M Dec/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Incyte USD 367.97M 46.53M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Ligand Pharmaceuticals USD 66.78M 83.54M Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 5.3B 530M Mar/2026
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
TG Therapeutics USD 51.69M 19M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026
Xencor USD -51.05M 55.28M Dec/2025